Gsk bevacizumab patent?

Short answer: GSK does not own the core bevacizumab patent. Bevacizumab (Avastin) was developed by Genentech, a subsidiary of Roche. The primary patents covering bevacizumab have historically been held by Genentech/Roche, not GSK. Over time, many of the key composition/use patents have expired or are nearing expiration, and several biosimilar players are now in the market or in development. There may be other, more specific GSK filings (for related technologies, formulations, methods, or uses) but not a standalone “GSK bevacizumab patent” covering the original antibody itself.

If you want to dig into patent details, I can help you look up region-specific status. A few good next steps:
- Search patent databases for “bevacizumab” with assignee “Genentech” or “Roche” to map core patents.
- Search for any “GSK” filings that mention bevacizumab to see if GSK has related or dependent claims (e.g., formulations, combinations, methods of treatment, or production).
- Check key jurisdictions (US, Europe/EPO, WIPO) and note expiration dates and any pediatric/exclusivity extensions or data exclusivity.

Would you like me to pull a region-specific patent landscape for bevacizumab and/or search for any GSK-related filings mentioning bevacizumab? If yes, tell me the country or region and whether you want a high-level summary or exact patent numbers.